ClinicalTrials.Veeva

Menu

Blood Screening for Adult Colorectal Cancer (BACCHUS)

U

University Hospital, Lille

Status

Enrolling

Conditions

Cancer Colorectal

Study type

Observational

Funder types

Other

Identifiers

NCT05577143
2022-A00223-40 (Other Identifier)
2021_0220

Details and patient eligibility

About

Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.

Enrollment

303 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with suspected colorectal cancer for which colonoscopy is indicated.
  • Patients between 50 and 75 years old, asymptomatic from the digestive point of view (for example referred for colonoscopy as part of a pre-operative check-up of an inguinal hernia or 3 months after an episode of complicated sigmoiditis), for whom a follow-up colonoscopy is indicated.

Note.

  • If the post-inclusion colonoscopy is normal, no biopsy will be performed and patients will be assigned to the control group.
  • If the colonoscopy performed after inclusion is abnormal (presence of at least one mucosal lesion), patients will be assigned to the "colorectal cancer" group or to the "polyps" group depending on the results of the anatomopathological analysis of the lesion(s)

Exclusion criteria

  • All clinical situations outside of CRC that could increase TFPI-1 or 2 blood levels: acute coronary syndrome (unstable angina, acute myocardial infarction), severe sepsis, decompensated cirrhosis, pregnancy, chronic inflammatory bowel disease (Crohn's or ulcerative colitis), colitis or radiation rectitis.
  • Endoscopic polypectomy without prior histological confirmation.
  • Emergency (occlusion or peritonitis)
  • Minor patients.
  • Persons of full age under legal protection or unable to express their consent
  • Persons not affiliated to a social security system or beneficiaries of such a system.
  • Pregnant women, women in labor or nursing mothers.

Trial design

303 participants in 3 patient groups

Case group
Description:
All consecutive patients from participating centers with an abnormal colonoscopy (presence of mucosal lesions at endoscopy), with histological confirmation of colorectal cancer. These will be patients with one or more histologically confirmed adenocarcinomatous lesions (CRC+) located in the colonic frame or rectum, with or without synchronous liver metastases.
Control group
Description:
All consecutive patients between 50 and 75 years of age for whom colonoscopy will be normal (no mucosal lesions). In this situation, histological examination is not performed.
Polyp group
Description:
All consecutive patients for whom colonoscopy shows mucosal lesions that will be classified as polyps after histological examination.

Trial contacts and locations

1

Loading...

Central trial contact

Philippe ZERBIB, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems